Chargement en cours...
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Outcomes for those diagnosed with acute myeloid leukemia (AML) remain poor. It has been widely established that persistent residual leukemic burden, often referred to as measurable or minimal residual disease (MRD), after induction therapy or at the time of hematopoietic stem cell transplant (HSCT)...
Enregistré dans:
| Publié dans: | J Clin Med |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5615280/ https://ncbi.nlm.nih.gov/pubmed/28925935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm6090087 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|